Brubru
EU policy intelligence
Regulation (EU) No 536/2014 replaced a fragmented directive-based regime with one application through the EU Clinical Trials Information System (CTIS), a coordinated assessment led by a reporting Member State, and a single decision per Member State. Adopted in 2014, it became applicable on 31 January 2022 once CTIS was certified fully functional.
One portal, one coordinated assessment, one decision per Member State
Before the Clinical Trials Regulation (CTR), the EU's clinical trials framework rested on Directive 2001/20/EC. Sponsors wishing to run a multi-country trial had to submit separate national applications, each assessed under different timelines and requirements. The patchwork discouraged pan-European trials, inflated costs, and reduced Europe's attractiveness as a trials location against the US and Asia.
The CTR replaced this with a single-submission model through the Clinical Trials Information System (CTIS), the EU portal and database operated by the EMA. One dossier is filed; a reporting Member State coordinates the joint scientific assessment (Part I); each concerned Member State conducts its own ethical and national assessment (Part II); and each Member State issues one single decision within 5 days of the reporting date. Recital 5 explains the deliberate choice of a Regulation over a Directive: sponsors must be able to rely on the same rules directly across all Member States.
The CTR was adopted on 16 April 2014 and published in OJ L 158 on 27 May 2014. Unlike a typical regulation, it did not become applicable six months after publication. Article 82(3) made its application conditional on the European Commission publishing a notice that CTIS was fully functional. That notice appeared on 31 July 2021, triggering application from 31 January 2022, eight years after adoption.
A three-year transition period followed. From 31 January 2023, all new trial applications had to be submitted through CTIS under the CTR. Trials authorised under the old Directive before that date had until 31 January 2025 to migrate to CTIS; after that date, the old Directive ceased to apply entirely. The CTR thus did not fully displace the old regime until eleven years after its adoption.
The CTR rests on two TFEU legal bases: Article 114 (internal market harmonisation) and Article 168(4)(c) (high standards of quality and safety for medicinal products). Recital 82 stresses that both bases are inseparable: trial harmonisation serves the internal market for medicines and simultaneously delivers a high level of health protection. The ordinary legislative procedure applied throughout.
The regulation is structured in 19 Chapters across 99 articles, supported by 85 recitals and 7 Annexes. Chapter I sets out scope and definitions. Chapters II through III cover authorisation and modifications. Chapters IV through XVI address every stage of a trial's life. Chapters XIV through XV establish the IT infrastructure (CTIS). Chapters XVII through XIX contain comitology, repeal, transitional and final provisions.
Data protection cross-references in the CTR point to Directive 95/46/EC and Regulation (EC) No 45/2001. Both are now superseded: read those references as the GDPR (Regulation (EU) 2016/679) and Regulation (EU) 2018/1725.
The Accelerating Clinical Trials in the EU (ACT EU) initiative, launched by the EMA, HMA and Commission in 2022, is the active workstream seeking to improve CTR delivery in practice. CTIS usability has been a recurring industry concern since go-live. The CTR is not part of the 2023 general medicines reform package targeting Directive 2001/83/EC and Regulation (EC) No 726/2004; it sits alongside that reform as the clinical trials pillar.
The "clinical study" umbrella: 35 definitions in Art 2 and three nested categories
Article 2 provides 35 definitions. At the top of the hierarchy sits clinical study (any investigation in humans to understand a medicinal product's effects). Three nested sub-categories carry different regulatory burdens.
The CTR applies to all clinical trials conducted wholly or partly within the EU (Art 1). It does not apply to non-interventional studies. It covers investigational medicinal products (IMPs) plus auxiliary medicinal products used to support a trial (background therapy, challenge agents, rescue medicine) but not acting as the investigational product themselves.
Article 90 contains an absolute prohibition: no gene therapy trials that would result in modifications to the germline. This goes beyond ordinary scope into substantive prohibition.
Chapter II (Arts 4-14): single portal, coordinated assessment, single decision
The sponsor submits the application dossier (detailed in Annex I and Annex II) via CTIS. The reporting Member State validates the application within 10 days, checking completeness. If the dossier is incomplete, the sponsor has a set period to provide additional information; the clock pauses. A validated application triggers the 45-day assessment clock.
Part I covers the scientific aspects common to all concerned Member States: the risk-benefit balance of the IMP, GCP compliance, investigator suitability, the adequacy of the IMP manufacturing, and the trial design. It runs in three sub-phases (Art 6(5)):
For ATMP or biotechnology-derived products, a further 50-day extension applies for expert consultation. Additional information requests pause the clock; the sponsor has up to 31 days to respond (Art 6(7)).
Each concerned Member State assesses Part II independently and in parallel with Part I. Part II covers national and ethics-committee aspects: subject protection measures, informed consent suitability, the trial's compatibility with national law, data protection compliance, and the ethics committee opinion. A negative ethics opinion grounds refusal. Part II is also due within 45 days of validation. Member States may diverge from the reporting Member State's Part I conclusion only on specified grounds (Art 8(4)): when the trial would present an unacceptable risk for subjects in their territory, or when the IMP conditions differ from the Part I assessment in specific national circumstances.
Each concerned Member State issues one single decision within 5 days of the reporting date, taking into account both the consolidated Part I report and its own Part II conclusion (Art 8). If no decision is issued by the deadline, silence counts as authorisation from the reporting Member State (tacit authorisation under Art 8(6)). The five-day window ensures rapid clearance once the substantive assessment is complete. An authorisation expires if no subject is enrolled within 2 years (Art 8(9) -- sunset clause).
Article 14 allows a sponsor to add a new concerned Member State after the trial has been authorised. The new Member State has 52 days from receipt to assess Part II and issue its decision. The existing Part I conclusion is used directly; only the national/ethical assessment runs afresh. This is the mechanism that allows a trial to expand geographically after initial approval.
Chapter III (Arts 15-24): same coordinated logic applied to post-authorisation changes
A substantial modification is any change to a CTR-authorised trial that is likely to have a substantial impact on the safety or rights of subjects, the reliability of data, or the conduct of the trial (Art 15). Examples include changes to the primary endpoint, the subject population, the IMP dose, or the trial protocol. Non-substantial administrative changes do not require a separate modification procedure.
The modification procedure runs the same coordinated logic as the initial authorisation, but with compressed timelines: validation within 6 days and assessment within 38 days (Arts 17-19). Part I modifications affecting all Member States are assessed jointly; Part II modifications are assessed by each affected Member State.
Chapter V (Arts 28-35): the cardinal principle that subject rights prevail over all other interests
Article 3 establishes the cardinal ethical anchor: the rights, safety, dignity and well-being of trial subjects must prevail over the interests of science and society. All applicable safety provisions must be respected, and data must be reliable and robust. Article 28 operationalises this by requiring, before any subject inclusion, an independent ethics committee opinion, that the trial is scientifically sound and based on the state of the art, that expected benefits outweigh risks, that the protocol is approved by a qualified medical professional, and that subject medical care is integrated into the trial.
Consent must be: (a) freely given, (b) specific to the trial, (c) informed -- based on a prior interview with an investigator giving information in language the subject understands, in writing, dated and personally signed. The consent document must cover the nature, significance, implications and risks of the trial. If new information becomes available that may be relevant, the consent must be updated. In cluster trials, simplified consent arrangements are permitted (Art 30) where the methodology justifies it and the ethics committee agrees.
Written consent from the legally authorised representative (parent or guardian). Where the minor is capable of forming an opinion, their own view must be sought and respected. Once the minor reaches legal age during the trial, their own consent must be obtained. The trial must either benefit the minor or relate to a condition affecting minors and generate knowledge relevant to that population with no equivalent adult-only trial available.
Consent from the legally authorised representative. The subject's previously expressed wishes must be considered. Inclusion requires that the trial could not be conducted with subjects capable of giving informed consent, the trial relates to the subject's condition, and it either directly benefits the subject or generates knowledge relevant to that population. Stricter protections apply to a subject who later regains capacity.
Special conditions apply: the trial must be capable of producing direct benefit for the woman, the foetus or the child, or relevant knowledge with no alternative trial available. The trial must not expose the foetus or neonate to risks beyond acceptable levels. The same standard consent process applies; the specific risks to the pregnancy and foetus must be covered in the consent documentation.
Where a subject's life-threatening condition requires immediate action and consent cannot be obtained from the subject or their representative before inclusion, the trial protocol may permit emergency inclusion under strict conditions: the intervention falls within the trial design, it is a medical emergency with no alternative available, the ethics committee has specifically approved the emergency provision, the subject or representative is informed as soon as practicable, and retrospective consent (or its withdrawal) is obtained without delay. The trial master file must document every emergency inclusion with full justification.
Chapter VI (Arts 36-39): notifications and mandatory transparency obligations
Chapter VII (Arts 40-46): the EudraVigilance reporting chain
Safety events flow through a defined chain from investigator to sponsor to EMA, with strict deadlines at each step. All reporting is through the EudraVigilance database module (Art 40).
| Event | Reporter | Recipient | Deadline |
|---|---|---|---|
| Serious Adverse Event (SAE) | Investigator | Sponsor | 24 hours |
| SUSAR -- fatal or life-threatening | Sponsor | EMA (EudraVigilance) | 7 days |
| SUSAR -- all others | Sponsor | EMA (EudraVigilance) | 15 days |
| Annual Safety Report | Sponsor | Concerned Member States + EMA | Once per year |
| Serious breach / urgent safety measure | Sponsor | Concerned Member States via CTIS | 7 days |
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is an adverse reaction that is unexpected (not consistent with the reference safety information in the Investigator's Brochure), serious (fatal, life-threatening, causing hospitalisation, disability, birth defect, or medically significant), and suspected to be related to the IMP. The sponsor must report SUSARs to EMA through EudraVigilance regardless of whether the trial involves multiple Member States. The EMA forwards relevant SUSARs to all concerned Member States.
Chapter VIII (Arts 47-59): good clinical practice, monitoring, master file, serious breaches
Article 47 requires that all trials comply with GCP as set out in the Regulation and its guidelines, which shall be consistent with the ICH E6 GCP guidelines. GCP covers protocol design, monitoring, audit, recording, analysis and reporting of clinical data in a manner that ensures credibility and integrity. The Commission may update the guidelines by delegated act.
The investigator site must be suitable (adequate facilities, qualified personnel, emergency equipment) before any subject is enrolled. Monitoring by the sponsor must be proportionate to the risk and complexity of the trial.
The sponsor and investigator must each maintain a clinical trial master file documenting every aspect of the trial: protocol, authorisation correspondence, consent forms, monitoring reports, audit reports, SUSAR reports, and all correspondence with regulators. The master file must be retained for at least 25 years after the end of the trial. If the sponsor transfers ownership of the data, the new owner assumes the archival obligation. An electronic audit trail is mandatory.
If a serious breach of the CTR or the trial protocol is detected (a deviation likely to significantly affect subjects' safety or rights, or data reliability), the sponsor notifies the concerned Member States within 7 days through CTIS. Similarly, if the sponsor or investigator takes an urgent safety measure -- an immediate action to protect subjects from a newly identified risk -- they notify concerned Member States within 7 days. Urgent safety measures may be implemented before receiving authorisation, but notification is immediate.
Chapters IX-X (Arts 60-70): GMP, qualified person, Annex VI labelling rules
Every manufacturer or importer of IMPs must hold a manufacturing/import authorisation from the competent authority of the relevant Member State. A qualified person (QP) -- a named individual meeting the education and experience requirements of Directive 2001/83/EC -- must certify each batch of IMP as compliant with GMP before it is used in a trial. The QP certification must be recorded in a register accessible to the competent authority. IMPs imported from third countries require the same batch certification; an EU-equivalent GMP certificate from the third country may substitute for an EU QP re-certification under bilateral agreements.
IMP labels must carry specific information set out in Annex VI, including: clinical trial reference, trial number, sponsor name and address, IMP code, batch number, subject identification code, route of administration, pharmaceutical form, dosage, storage conditions, expiry date, and the statement "For clinical trial use only." Language requirements are set by the Member State; labels may be in the language of the Member State where the trial is conducted. Simplified labelling is permitted where the IMP is accompanied by a full package leaflet or product sheet.
Chapters XI-XII (Arts 71-76): responsibilities, EU legal representative, national compensation schemes
The sponsor is responsible for initiating and managing the trial, financing it (unless delegated), ensuring GCP compliance across all sites, and submitting all required notifications to CTIS. Multiple co-sponsors may share responsibilities by written agreement, naming a lead sponsor for CTIS purposes. The sponsor may delegate specific tasks to a Contract Research Organisation (CRO) but cannot delegate ultimate regulatory responsibility.
A sponsor established outside the EU must designate an EU legal representative established in a Member State. The representative is the single EU point of contact for all regulatory and liability purposes. As an alternative for non-commercial sponsors, a contact person established in the EU is sufficient. The distinction matters: a legal representative carries full liability; a contact person does not. All CTIS submissions from a non-EU sponsor must identify the representative or contact person.
Member States must ensure adequate compensation systems for trial-related harm. This may be implemented through insurance, indemnity schemes, or no-fault compensation funds. For low-intervention clinical trials, Art 76(3) allows a lighter-touch arrangement reflecting the reduced risk -- sponsors need not take out full clinical-trial insurance if the trial uses an authorised IMP under its marketing authorisation with only minimal additional risk.
Chapter XIII (Arts 77-79): Member State corrective measures and Commission controls
Competent authorities may suspend, prohibit or require modification of an ongoing trial if: (a) the authorisation conditions are no longer met; (b) there is doubt about the safety or scientific validity; (c) the sponsor has failed to notify required information; (d) a serious breach has occurred. The decision must be communicated to the sponsor through CTIS within defined timelines. Urgent protective measures may be taken immediately and reported afterwards.
Member States must carry out inspections at trial sites, sponsor premises and manufacturing sites to verify compliance with the CTR. Inspection findings are recorded and communicated via CTIS. The Commission may conduct Union-level controls in Member States to verify their national inspection systems and to investigate persistent or systemic non-compliance. Commission controls do not replace Member State inspections but provide a top-level audit function. Results are published.
Chapter XIV (Arts 80-82): the IT backbone that unlocked the entire regulation
The EU portal is the single entry point for all CTR interactions: submissions, validation, assessment, notifications, and correspondence between sponsors, Member States and the EMA. Each trial receives a unique EU trial number on submission. The portal coordinates the Part I and Part II parallel workflows and timestamps every action to enforce the regulatory deadlines. All documents submitted through the portal constitute the official record.
The EU database is publicly accessible and searchable by trial number, IMP, sponsor, condition, country, phase and status. It contains: the trial application dossier (minus confidential commercial information), assessment reports, authorisation decisions, modifications, notifications (start, end, results), SUSARs (anonymised aggregate), and results summaries including layperson summaries. Subject personal data is never published. The design reflects recital 67's commitment that the public has a right to know which trials are being conducted in the Union.
Article 82 was the novel mechanism that deferred application: the regulation would become applicable only six months after the Commission published a notice confirming CTIS was fully functional. CTIS was built under EMA oversight; delays in development, testing and stakeholder readiness pushed the go-live notice to 31 July 2021, producing the 31 January 2022 application date. The EMA launched CTIS into full operation on that date. This delay mechanism was intentional: rather than force Member States and sponsors into a broken IT system, the law waited for the infrastructure to be ready.
Chapters XV-XVI (Arts 83-87): coordination governance and cost-recovery
CTAG (Art 85) consists of the national contact points designated by each Member State (Art 83). It is chaired by the Commission and coordinates the application of the CTR across the Union. CTAG's mandate covers: guidance on the application of CTR provisions, coordination of Member State inspection programmes, discussion of implementation problems, and advice to the Commission on technical and scientific aspects. CTAG does not make binding decisions; its role is advisory and coordinatory.
Member States may charge fees for assessment activities. The CTR requires that the total fee charged per trial by all concerned Member States is a single payment to the reporting Member State, which then distributes shares. This prevents multiple parallel fee invoices from different Member States. The fee must be based on cost-recovery principles. Member States may reduce or waive fees for non-commercial sponsors (academic, non-profit) and for trials involving rare diseases or paediatric populations, reflecting the public-health interest in these trials (recital 83).
Every headline number from the CTR's 99 articles in one table
| Deadline / threshold | Value | Article | Note |
|---|---|---|---|
| Validation of application | 10 days | Art 5 | Reporting Member State checks completeness; clock pauses if additional info requested |
| Part I -- initial assessment phase | 26 days | Art 6(5) | Reporting Member State drafts initial assessment report |
| Part I -- coordinated review phase | 12 days | Art 6(5) | All concerned Member States comment |
| Part I -- consolidation phase | 7 days | Art 6(5) | Final consolidated Part I report issued |
| Part I total (standard) | 45 days | Art 6(3) | From validation; +50 days for ATMP/biotech; +31 days for additional info |
| Part II total | 45 days | Art 7 | National/ethics assessment runs in parallel with Part I |
| Single decision per Member State | 5 days | Art 8 | From reporting date; silence = tacit authorisation from reporting MS |
| Adding a Member State | 52 days | Art 14 | New MS assesses Part II only; existing Part I conclusion applies directly |
| Authorisation expiry (sunset) | 2 years | Art 8(9) | If no subject enrolled within 2 years of authorisation |
| Substantial modification validation | 6 days | Art 17 | Reporting Member State validates modification dossier (Annex II) |
| Substantial modification assessment | 38 days | Arts 18-19 | Same coordinated Part I + Part II logic as initial authorisation |
| Trial start notification | 15 days | Art 36(1) | From first subject-enrolment act in any concerned Member State |
| Trial end notification | 15 days | Art 36(4) | From last trial-related visit by last subject in any Member State |
| Results summary (all outcomes) | 1 year | Art 37(4) | From global trial end; layperson summary submitted alongside |
| Clinical study report | 30 days | Art 37(6) | After marketing authorisation decision or refusal for the IMP |
| SAE: investigator to sponsor | 24 hours | Art 42 | Serious Adverse Event at the trial site |
| SUSAR: fatal or life-threatening | 7 days | Art 42 | Sponsor to EMA (EudraVigilance); follow-up within 8 additional days |
| SUSAR: all others | 15 days | Art 42 | Sponsor to EMA (EudraVigilance) |
| Serious breach notification | 7 days | Art 52 | Sponsor to concerned Member States via CTIS |
| Urgent safety measure notification | 7 days | Art 54 | Sponsor to concerned Member States; measure may be implemented before notification |
| Clinical trial master file archive | 25 years | Art 58 | From end of trial; electronic audit trail mandatory |
35 defined terms in Chapter I; the most operationally significant are listed here
Investigational medicinal product (IMP): a medicinal product being tested or used as a reference, including a placebo. The IMP is what the trial investigates. An auxiliary medicinal product (AxMP) is used to support a trial (background therapy, rescue medicine, challenge agent) but is not itself the investigational product. IMPs and AxMPs have different labelling, manufacturing and supply rules under the CTR.
Sponsor: an individual, company, institution or organisation that takes responsibility for initiating, managing and financing a trial. Investigator: a healthcare professional responsible for conducting the trial at a trial site. Principal investigator: the investigator responsible for a team of investigators at a site when a trial is conducted by a team. The sponsor and investigator may be the same person in academic investigator-initiated trials.
The Member State selected (by the sponsor or, in case of disagreement, by the Commission) to lead the Part I coordinated scientific assessment for a multi-country trial. The reporting Member State drafts the initial Part I assessment, manages the coordinated review, and produces the final consolidated report. Its coordinating role does not override each individual Member State's sovereign right to make its own Part II decision on national/ethical grounds.
CTIS (Clinical Trials Information System): the EU portal and database operated by the EMA. All CTR interactions -- submissions, assessments, notifications, results -- pass through CTIS. Each trial receives a unique EU trial number on submission, which serves as the persistent identifier throughout the trial lifecycle and in the public database. CTIS replaced the older EudraCT database for new trials from January 2023.
Essential acronyms and terms for working with the CTR
From the predecessor directive to the CTIS transition completion
Primary documentation for Regulation (EU) No 536/2014
Six tools to analyse, track and work with EU clinical trials legislation